The FDA clearance for Tandem Diabetes Care's new insulin pump is a significant positive development for the company. This regulatory approval not only validates the safety and efficacy of the product, but also allows the company to market and sell the product in the US. This could potentially lead to increased revenues and profitability for the company, which is likely to have a positive impact on the company's stock price in the short term.